Abstract:A tetranuclear Cu(II) complex of a pentadentate ligand, containing pyridine2,6‐diamide motif, is reported. The X‐ray structure of the complex reveals that it has an open book type architecture. The magnetic property of the complex is explored by VT susceptibility measurements and DFT calculations. The complex shows strong antiproliferative activity against HCT116 cancer cells. Possible mechanism of anticancer activity is also discussed. A pentadentate diamide ligand, N,N′‐di(pyridine‐2‐yl)pyridine‐2,6‐dicarboxamide (L1H2) and its tetranuclear Cu(II) complex [Cu4(L1)2(μ3‐OH)2(H2O)3(ClO4)](ClO4) ⋅ H2O are reported. X‐ray crystal structure of the complex reveals that it has an open‐book type architecture. Two central copper atoms are connected to each other by two hydroxo bridges. Each of these two hydroxo bridges also connects the two central copper atoms to one of the two terminal copper atoms. Variable temperature susceptibility measurements show that χMT decreases with the temperature, indicating a strong antiferromagnetic behavior. With the help of DFT calculations the magnetic data was analyzed using the spin Hamiltonian H=−2 J1S3 ⋅ S4 −2 J2(S3 ⋅ S1+ S3 ⋅ S2+ S4 ⋅ S1+ S4 ⋅ S2)−2 J3S1 ⋅ S2 (where subscripts 1 and 2 refer to the terminal copper atoms and 3 and 4 refer to the central copper atoms). The best fit was obtained with 2 J1=−322 cm−1, 2 J2=+34.8 cm−1, 2 J3=−8.8 cm−1 and g=2.18, indicating a δ‐type interaction between terminal copper atoms. The complex proves to be an avid binder of ct‐DNA, with apparent binding constant (Kapp) value estimated as 1.536×107 M−1. In vitro experiments indicate that the Cu(II) complex reduced the proliferation of HCT116 cells among other cell lines. This reduction of cell proliferation may be attributed to the enhancement of intracellular ROS, along with modulation and disruption of cell cycle associated proteins. SKC conceptualized the project, arranged funding and involved in overall coordination among collaborators, analyzing the data, and writing the paper. AM was involved in doing the experimental work on synthesis of the compounds, carrying out analytical and spectroscopic measurements, collecting X‐ray crystallographic data and DNA binding experiments. MS, SM and KDS were involved in study of anticancer activities of the complex. SS helped in refining X‐ray structure of the complex. MC did the magnetic measurements and analysis whereas AF did the DFT calculations.

Novel Octahedral Nickel (II) Complex with Flexible Piperazinyl Moiety Exhibits Potent Cytotoxic Effect Along with Anti‐Migratory and Anti‐Metastatic Effect on Human Cancer Cells.

Structural Design, Anticancer Evaluation, and Molecular Docking of Newly Synthesized Ni(II) Complexes with ONS-Donor Dithiocarbazate Ligands

Copper-Plumbagin Complex Produces Potent Anticancer Effects by Depolymerizing Microtubules and Inducing Reactive Oxygen Species and DNA Damage

Nickel(Ii) And Copper(Ii) Complexes Constructed With N2s2 Hybrid Benzamidine-Thiosemicarbazone Ligand: Synthesis, X-Ray Crystal Structure, Dft, Kinetico-Catalytic And In Vitro Biological Applications

Morpholine or methylpiperazine and salicylaldimine based heteroleptic square planner platinum (II) complexes: In vitro anticancer study and growth retardation effect on E. coli.

Synthesis, Dna/Bsa Binding Studies And In Vitro Biological Assay Of Nickel(Ii) Complexes Incorporating Tridentate Aroylhydrazone And Triphenylphosphine Ligands

Synthesis, kinetics, mechanisms, and bioactivity evaluations of a novel Zn(II) complex

Bio-physical and theoretical investigations on Pt(II)-pyridine based complexes with relevant bio-molecules for the development of potent anticancer drug candidates

Synthesis of Amino Acid Schiff Base Nickel (II) Complexes as Potential Anticancer Drugs In Vitro

Anti-cancer and anti-angiogenic activities of some synthetic Ni(II) thiosemicarbazone complexes

Synthesis, Characterization and Anti-Cancer Activity of gold (III) and Nickel (II) Metal Ion Complexes Derived from Tetrazole-Triazole Compound

Deliberate-Characterization for Ni(II)-Schiff Base Complexes: Promising In-Vitro Anticancer Feature that Matched MOE Docking-Approach

Designing metal chelates of halogenated sulfonamide Schiff bases as potent nonplatinum anticancer drugs using spectroscopic, molecular docking and biological studies

Synthesis, Characterization and Anticancer Activities of Transition Metal Complexes with a Nicotinohydrazone Ligand.

A comprehensive study on synthesis and crystal structures of Cu(II) and Ni(II) complexes: In vitro and in silico evaluation of biomolecular interactions, antiproliferative activities and molecular docking

Dithiocarbazate–Fe III , −Co III , −Ni II , and −Zn II Complexes: Design, Synthesis, Structure, and Anticancer Evaluation

Mixed Ligand Mononuclear Copper(II) Complex as a Promising Anticancer Agent: Interaction Studies with DNA/HSA, Molecular Docking, and In Vitro Cytotoxicity Studies.

Dithiocarbazate ligands and their Ni(II) complexes with potential biological activity: Structural, antitumor and molecular docking study

Novel Nickel(II) complex bearing acenaphthenequinone based thiosemicarbazone bis -Schiff Base: Synthesis, characterization, linkage isomers, antitumor activity, DFT, and DNA docking simulation

A Tetranuclear copper(II) Complex with a Pyridine‐2,6‐dicarboxamide Ligand: Structural and Magnetic Properties and In vitro Antiproliferative Activity Against Human Cancer Cells

Effect of geometric isomerism on the anticancer property of new platinum complexes with glycine derivatives as asymmetric N, O donate ligands against human cancer